Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Czech | Denmark | Dominican Republic | Ecuador | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Ukraine | United Kingdom | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Ferring
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Belgium, Canada, China, Czech Republic, Denmark, France, Germany, India, Israel, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom, United States
Active Clinical Trial Count: 12
Highest Development Phases
Phase 3: Infertility|Infertility, Female|Infertility, Male
Phase 2: Asthenozoospermia
Phase 1: Ovarian Cysts|Pregnancy Outcomes|Pregnancy, Ovarian
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ADAM | P2 |
Active, not recruiting |
Asthenozoospermia|Infertility, Male |
2027-01-27 |
|
| Celestial-1 | P1 |
Recruiting |
Pregnancy Outcomes|Pregnancy, Ovarian|Ovarian Cysts |
2026-11-11 |
|
| 2023-508430-34-00 | P2 |
Recruiting |
Asthenozoospermia|Infertility, Male |
2026-07-15 |
|
| ADAM | P2 |
Recruiting |
Infertility, Male |
2026-07-15 |